NeOnc Technologies (Nasdaq: $NTHI) announces new findings showing that ultrasound enhances the potency of NEO100 in treating primary and metastatic brain tumors. A breakthrough at the intersection of AI, oncology, and precision medicine. #NTHI #AIinMedicine #Biotech

🚨 NeOnc completes enrollment in its pivotal NEO100 Phase 2a trial for IDH1-mutant recurrent glioma. Preliminary data coming Q2 2026. This milestone follows positive results from a 24-patient cohort shared on the Nov. 12 investor call. https://t.co/8q9vPGs86p #NTHI #NEO100

NeOnc Technologies (NTHI) is honored to announce that His Highness Sheikh Nahyan bin Zayed Al Nahyan has assumed the role of Executive Chairman of NuroMENA, our Middle East subsidiary — marking a new era in UAE–US collaboration against brain cancer. 🇦🇪🇺🇸🧠 https://t.co/ociPVqjA06

As a Director of the biotech company @NeOncTechInc bringing brain cancer treatments to market, this independent analysis is spot on: (1) "NeOnc is at a key inflection point from a survival story to a growth story" Kudos to the team!

The brain has a natural barrier that blocks most drugs from reaching where they are needed. @NeOncTechInc is changing that. If you missed this episode, you can watch it now at https://t.co/alJFTff3J9. Follow us and @drdrew to stay on top of everything health.

We’re going on @HUwithDrDrew! 🎉 📅 Sept 25 | ⏰ Airs nationwide at 8 AM| Lifetime TV Hear from Dr. Chen (Founder & CEO) & Amir Heshmatpour (President & Executive Chairman) about how @NeOncTechInc is redefining brain cancer treatment. Plus, Adeline, a remarkable NEO-100

We’re excited to be part of the American Brain Tumor Association 2025 National Conference! 💡 At @NeOncTechInc, we’re driven by innovation and the belief that together we can create better outcomes for patients and their families. 📍 Stop by and visit us at the event! #BTSM

In the latest episode of Trader Talk @YahooFinance , I speak with Amir Heshmatpour, executive chairman and president of NeOnc Technologies $NTHI. Amir explains NeOnc’s focus on intranasal drug delivery for brain cancer, the significance of its partnership with USC’s medical

💡 Innovating Treatment. Improving Lives. At NeOnc Technologies, we’re pushing boundaries with intranasal therapies that overcome the blood-brain barrier—targeting brain tumors like GBM, meningioma, and high-grade gliomas. ⁠ 🔬 Now enrolling for clinical trials: • NEO100 for

Dr. Thomas Chen, Founder of NeOnc Technologies Holdings Inc., discusses our mission to innovate brain cancer treatment and bring new hope to patients. From pioneering intranasal drug delivery systems to advancing clinical research, NeOnc is committed to transforming healthcare

A historic moment for NeOnc Technologies Holdings Inc.! 🎉 Our Executive Chairman, Amir Heshmatpour, and CEO, Dr. Thomas Chen, had the honor of ringing the opening bell at Nasdaq. This marks a significant milestone for the company and reflects our growth and commitment to

A Trojan innovation just made it to Wall Street. NeOnc — founded by @KECKSchool_USC neurosurgeon Thomas Chen — just went public. Its intranasal drug delivery system is designed to fight brain cancer, bringing USC research directly to patients. 🧠

Congrats to inventor and neurosurgeon Dr. Thomas Chen and his co-founder, Amir Heshmatpour, on @NeOncTechInc's direct @Nasdaq listing! It's the first USC-licensed biotech company with agreements through USC Stevens to go public. Excited to see Trojan innovation on Wall Street!✌️

Our Opening Bell ceremony at Nasdaq is live! 🔔 Watch the moment + hear from our Executive Chairman Amir Heshmatpour and CEO/Founder Dr. Thomas Chen as they share the vision behind NeOnc Technologies. #NeOnc #NTHI #Nasdaq #IPO #Biotech #Leadership https://t.co/3Qd3jeX50g

We’re thrilled to announce that NeOnc Technologies Holdings, Inc. is now listed on the Nasdaq Global Market under $NTHI! Our team celebrated this achievement by ringing the Opening Bell at Nasdaq MarketSite in Times Square. Here's to advancing our mission in CNS therapeutics!

We’ve taken a significant step forward in our mission to advance neuro-oncology by filing a registration statement on Form S-1 with the SEC. As part of this process, we’ve also applied to list on NASDAQ under the ticker symbol NTHI and are awaiting final approval. Stay tuned as

NeOnc Technologies is pioneering a novel approach that leverages the olfactory nerve for targeted drug delivery to the brain and bypasses traditional barriers. Learn more: https://t.co/5BxQ6CxbPo

NeOnc Technologies Founder & CEO, Dr. Thomas Chen, recently joined Ira Pastor on his show to discuss our pioneering approach to drug delivery for brain cancer and CNS disorders. With our patented platform technology, we’re exploring a way to bypass the blood-brain barrier and

NeOnc Technologies Founder & CEO, Dr. Thomas Chen, recently joined Ira Pastor on his show to discuss our pioneering approach to drug delivery for brain cancer and CNS disorders. https://t.co/9cj9ZZgeIa